NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Start Multiple Choice Practice Test
Start Flash Cards

Practice this question and more.

Alemtuzumab (Lemtrada) requires enrollment in what program due to safety concerns?

  1. MEDWATCH Program

  2. REMS Program

  3. Patient Assistance Program

  4. SAFE Rx Program

The correct answer is: REMS Program

Alemtuzumab (Lemtrada) requires enrollment in the REMS (Risk Evaluation and Mitigation Strategy) Program due to safety concerns. The REMS program is a strategy to manage known or potential serious risks associated with a drug product and is required for certain medications with significant safety concerns. By enrolling in the REMS program, healthcare providers and patients are educated about these risks and how to minimize them, ensuring safe use of the medication. This program includes elements such as training, certification, dispensing restrictions, patient monitoring, and follow-up. The other options mentioned are not specifically designed to address safety concerns related to specific medications like the REMS program.

More Questions Like This